ICER has decided to extend its timeline for assessing beta-amyloid antibodies for early Alzheimer’s disease pending the biologics license application submissions for donanemab (Eli Lilly & Co.) and lecanemab (Eisai Co., Ltd).  An updated timeline for key dates is forthcoming, with a public meeting to present the Evidence Report findings expected to be held in the first quarter of 2023. 

Interventions of Interest:

  • donanemab (Eli Lilly & Co.)
  • lecanemab (Eisai Co., Ltd)
  • aducanumab (Aduhelm™, Biogen)

For questions, please contact Kelsey Gosselin, Program Manager, at kgosselin@icer.org.

View the Key Stakeholder List.